首页>
外国专利>
Intestinal metagenomic features are screening markers for the treatment of acarbose in type 2 diabetes
Intestinal metagenomic features are screening markers for the treatment of acarbose in type 2 diabetes
展开▼
机译:肠宏基因组学特征是2型糖尿病中阿卡波糖治疗的筛选标志
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention discloses that the intestinal metagenomic feature is used as a screening marker for the effect of treating acarbose in type 2 diabetes, and the intestinal microbial macrogen feature is Bacteroides intestinal type. In the present invention, by first using the concept of intestinal type, in type 2 diabetic patients with different intestinal parasitic fungal groups, it was discovered that the therapeutic effect on diabetes hypoglycemic drug, acarbose, was significantly different. Before using the medicine, the optimal treatment effect group is selected by dividing the intestinal type of the patient, and whether or not the individual type 2 diabetic patient is treated with diabetes using acarbose I can judge. In addition, in the normal classification of intestinal type, sequence measurement or PCR expansion using fecal parasite DNA is performed, but bile acid components, especially secondary bile acids, are not detected against intestinal type under baseline conditions. Since it has a good classification role and can realize differentiation of intestinal type through markers in blood, it is a marker used for diagnosis. [Selection] Figure 2
展开▼